PVLA Reports Positive Phase 3 SELVA and Phase 2 TOIVA Data for QTORIN Rapamycin, Showing 100% Improvement in Microcystic Lymphatic Malformations, 87% Reduction in Leaking/Bleeding Symptoms
Palvella Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $118.46
+1.8% in 3d after detection
Post-detection moves
1h
—
1d
+0.4%
3d
+1.8%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS